Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 Shows No Dose Limiting Toxicities Reported, Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14
Paul Quintaro